Journal article
Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: A consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer
EA Olsen, S Whittaker, YH Kim, M Duvic, HM Prince, SR Lessin, GS Wood, R Willemze, MF Demierre, N Pimpinelli, MG Bernengo, PL Ortiz-Romero, M Bagot, T Estrach, J Guitart, R Knobler, JA Sanches, K Iwatsuki, M Sugaya, R Dummer Show all
Journal of Clinical Oncology | Published : 2011
Abstract
Mycosis fungoides (MF) and Sé zary syndrome (SS), the major forms of cutaneous T-cell lymphoma, have unique characteristics that distinguish them from other types of non-Hodgkin's lymphomas. Clinical trials in MF/SS have suffered from a lack of standardization in evaluation, staging, assessment, end points, and response criteria. Recently defined criteria for the diagnosis of early MF, guidelines for initial evaluation, and revised staging and classification criteria for MF and SS now offer the potential for uniform staging of patients enrolled in clinical trials for MF/SS. This article presents consensus recommendations for the general conduct of clinical trials of patients with MF/SS as we..
View full abstractGrants
Funding Acknowledgements
Elise A. Olsen, BioCryst, Eisai, Johnson & Johnson, Yaupon Therapeutics, Genmab; Sean Whittaker, Gloucester Pharmaceuticals; Youn H. Kim, Kyowa Kirin, Merck, Allos Therapeutics, Yaupon Therapeutics, Eli Lilly, BioCryst, TenX Biopharma; Madeleine Duvic, Allos Therapeutics, BioCryst, Eisai, Therakos, Eli Lilly, Roche, Therakos, Yaupon Therapeutics; H. Miles Prince, Novartis, Gloucester Pharmaceuticals; Marie-France Demierre, Eisai, Genmab, Gloucester Pharmaceuticals, Merck, Novartis, Schering-Plough, Therakos; Pablo L Ortiz-Romero, TenX Biopharma, Bristol-Myers Squibb; Joan Guitart, Yaupon Therapeutics; Robert Knobler, Therakos; Reinhard Dummer, AstraZeneca, Novartis, Cephalon, Merck Sharp Dohme, Transgene, Bayer Pharmaceuticals; Sareeta Parker, Eisai, BioCryst; Lauren Pinter-Brown, Allos Therapeutics, Gloucester Pharmaceuticals; Michael Girardi, Pfizer; Steven Horwitz, Allos Therapeutics, Gloucester Pharmaceuticals; Steve Rosen, Celgene